Cell Therapeutics Inc. (CTIC) Reports Q1 Loss of $0.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Financial Fact:
Foreign exchange gain (loss): -69K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Foreign exchange gain (loss): -69K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q1 EPS of ($0.20), versus ($0.18) reported last year. Revenue for the quarter came in at $1.4 million, versus $1.1 million reported last year.
For earnings history and earnings-related data on Cell Therapeutics Inc. (CTIC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Enviri exits Deutsche Bahn contract, expects $19M net gain
- RBC Capital on Compass Pathways (CMPS): 'We See an Opportunity to Buy on Weakness'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
